+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hospital Infection Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851009
  • Report
  • September 2018
  • Region: Global
  • 208 pages
  • Transparency Market Research
1 of 2

Hospital Infection Therapeutics Market - Overview

This report studies the current as well as future prospects of the global hospital infection therapeutics market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of hospital infection therapeutics and new players planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. This section also provides the overall information and data analysis of the global hospital infection therapeutics market regarding leading segments based on infection, therapeutics, and region.

The global hospital infection therapeutics market has been segmented based on therapeutics, infection, and region. In terms of therapeutics, the global market has been classified into anti-bacterial drugs, anti-fungal drugs, anti-viral drugs, and others. The others segment comprises drug classes such as anti-parasitic drugs. The anti-bacterial drugs segment has been divided into cell wall synthesis inhibitors, protein synthesis inhibitors, and others. The anti-fungal drugs segment has been categorized into Caspofungin, Amphotericin B, and others. Based on infection, the global hospital infection therapeutics market has been segmented into hospital acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections, and other hospital infections.

The bottom-up approach for determining the market size was employed using various market indicators obtained from secondary sources, which include population in 2017, prevalence of all types of hospital acquired infections in major countries, variations in therapy cost across major regions, and approval of therapeutics in specific regions. The top-down approach was used to derive the market size for therapeutics segments, wherein revenues of all publicly listed market players were obtained through secondary sources and analyzed for hospital infection therapeutics specific revenues by narrowing down to revenue percentage for therapeutics segment through extensive secondary analysis of annual reports, investor presentations, press releases, primary interviews, and others. Data triangulation is based on secondary research (top-down and bottom-up approaches) and primary research. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2018 to 2026, considering 2017 as the base year.

The market overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have significant impact on the global hospital infection therapeutics market and could influence it in the near future. Market attractiveness analysis has been provided to explain the intensity of competition in the market across different regions. The competitive scenario among different market players has been evaluated through market share analysis in the competitive landscape section of the report. These factors are likely to help market players take strategic decisions to strengthen their positions and expand their shares in the global hospital infection therapeutics market. The report also comprises of regulatory scenario by region/global, pipeline analysis, reimbursement scenario by region/global, disease prevalence & incidence rate globally with key countries, health care industry overview, value chain analysis, and porter’s five forces analysis.

In terms of region, the global hospital infection therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The report also provides market size and forecast for major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and opportunities has been provided in the overview section. This section of the report also provides the market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global hospital infection therapeutics market.

Major players operating in the global hospital infection therapeutics market are Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, AstraZeneca, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Allergan plc, Sanofi S.A., Gilead Sciences, Inc., Basilea Pharmaceutica Ltd., and Bristol-Myers Squibb Company, among others.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hospital Infection Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Therapeutics Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hospital Infection Therapeutics Market Analysis and Forecast, 2016-2026
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1.Regulatory Scenario by Region/globally
5.2.Pipeline Analysis
5.3.Reimbursement Scenario by Region/globally
5.4.Disease Prevalence & Incidence Rate globally with key countries
5.5.Healthcare Industry Overview
5.6.Value Chain Analysis

6. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Therapeutics
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Forecast, by Therapeutics, 2016-2026
6.3.1. Antibacterial Drugs
6.3.1.1. Cell Wall Synthesis Inhibitors
6.3.1.2. Protein Synthesis Inhibitors
6.3.1.3. Others
6.3.2. Antifungal Drugs
6.3.2.1. Caspofungin
6.3.2.2. Amphotericin B
6.3.2.3. Others
6.3.3. Antiviral Drugs
6.3.4. Others
6.4. Market Attractiveness, by Therapeutics

7. Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Infection
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Forecast, by Infection, 2016-2026
7.3.1. Hospital Acquired Pneumonia
7.3.2. Urinary Tract Infections
7.3.3. Gastrointestinal Disorders
7.3.4. Bloodstream Infections
7.3.5. Surgical Site Infections
7.3.6. Other Hospital Infections
7.4. Market Attractiveness, by Infection

8. Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region

9. North America Hospital Infection Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Forecast, by Therapeutics, 2016-2026
9.2.1. Antibacterial Drugs
9.2.1.1. Cell Wall Synthesis Inhibitors
9.2.1.2. Protein Synthesis Inhibitors
9.2.1.3. Others
9.2.2. Antifungal Drugs
9.2.2.1. Caspofungin
9.2.2.2. Amphotericin B
9.2.2.3. Others
9.2.3. Antiviral Drugs
9.2.4. Others
9.3. Market Forecast, by Infection, 2016-2026
9.3.1. Hospital Acquired Pneumonia
9.3.2. Urinary Tract Infections
9.3.3. Gastrointestinal Disorders
9.3.4. Bloodstream Infections
9.3.5. Surgical Site Infections
9.3.6. Other Hospital Infections
9.4. Market Forecast, by Country, 2016-2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Therapeutics
9.5.2. By Infection
9.5.3. By Country

10. Europe Hospital Infection Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Forecast, by Therapeutics, 2016-2026
10.2.1. Antibacterial Drugs
10.2.1.1. Cell Wall Synthesis Inhibitors
10.2.1.2. Protein Synthesis Inhibitors
10.2.1.3. Others
10.2.2. Antifungal Drugs
10.2.2.1. Caspofungin
10.2.2.2. Amphotericin B
10.2.2.3. Others
10.2.3. Antiviral Drugs
10.2.4. Others
10.3. Market Forecast, by Infection, 2016-2026
10.3.1. Hospital Acquired Pneumonia
10.3.2. Urinary Tract Infections
10.3.3. Gastrointestinal Disorders
10.3.4. Bloodstream Infections
10.3.5. Surgical Site Infections
10.3.6. Other Hospital Infections
10.4. Market Forecast, by Country/Sub-region, 2016-2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Therapeutics
10.5.2. By Infection
10.5.3. By Country/Sub-region

11. Asia Pacific Hospital Infection Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Forecast, by Therapeutics, 2016-2026
11.2.1. Antibacterial Drugs
11.2.1.1. Cell Wall Synthesis Inhibitors
11.2.1.2. Protein Synthesis Inhibitors
11.2.1.3. Others
11.2.2. Antifungal Drugs
11.2.2.1. Caspofungin
11.2.2.2. Amphotericin B
11.2.2.3. Others
11.2.3. Antiviral Drugs
11.2.4. Others
11.3.Market Forecast, by Infection, 2016-2026
11.3.1. Hospital Acquired Pneumonia
11.3.2. Urinary Tract Infections
11.3.3. Gastrointestinal Disorders
11.3.4. Bloodstream Infections
11.3.5. Surgical Site Infections
11.3.6. Other Hospital Infections
11.4.Market Forecast, by Country/Sub-region, 2016-2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5.Market Attractiveness Analysis
11.5.1. By Therapeutics
11.5.2. By Infection
11.5.3. By Country/Sub-region

12. Latin America Hospital Infection Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Forecast, by Therapeutics, 2016-2026
12.2.1. Antibacterial Drugs
12.2.1.1. Cell Wall Synthesis Inhibitors
12.2.1.2. Protein Synthesis Inhibitors
12.2.1.3. Others
12.2.2. Antifungal Drugs
12.2.2.1. Caspofungin
12.2.2.2. Amphotericin B
12.2.2.3. Others
12.2.3. Antiviral Drugs
12.2.4. Others
12.3.Market Forecast, by Infection, 2016-2026
12.3.1. Hospital Acquired Pneumonia
12.3.2. Urinary Tract Infections
12.3.3. Gastrointestinal Disorders
12.3.4. Bloodstream Infections
12.3.5. Surgical Site Infections
12.3.6. Other Hospital Infections
12.4.Market Forecast, by Country/Sub-region, 2016-2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5.Market Attractiveness Analysis
12.5.1. By Therapeutics
12.5.2. By Infection
12.5.3. By Country/Sub-region

13. Middle East & Africa Hospital Infection Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Forecast, by Therapeutics, 2016-2026
13.2.1. Antibacterial Drugs
13.2.1.1. Cell Wall Synthesis Inhibitors
13.2.1.2. Protein Synthesis Inhibitors
13.2.1.3. Others
13.2.2. Antifungal Drugs
13.2.2.1. Caspofungin
13.2.2.2. Amphotericin B
13.2.2.3. Others
13.2.3. Antiviral Drugs
13.2.4. Others
13.3.Market Forecast, by Infection, 2016-2026
13.3.1. Hospital Acquired Pneumonia
13.3.2. Urinary Tract Infections
13.3.3. Gastrointestinal Disorders
13.3.4. Bloodstream Infections
13.3.5. Surgical Site Infections
13.3.6. Other Hospital Infections
13.4.Market Forecast, by Country/Sub-region, 2016-2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Israel
13.4.4. Rest of Middle East & Africa
13.5.Market Attractiveness Analysis
13.5.1. By Therapeutics
13.5.2. By Infection
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1.Market Player - Competition Matrix (By Tier and Size of companies)
14.2.Market Share Analysis By Company (2017)
14.3.Market Footprint Analysis
14.4. Competitive Business Strategies
14.5. Company Profiles
14.5.1. Allergan
14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.1.2. Product Portfolio
14.5.1.3. SWOT Analysis
14.5.1.4. Strategic Overview
14.5.1.5. Financial Overview
14.5.2. AstraZeneca
14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.2.2. Product Portfolio
14.5.2.3. SWOT Analysis
14.5.2.4. Strategic Overview
14.5.2.5. Financial Overview
14.5.3. Basilea Pharmaceutica Ltd.
14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.3.2. Product Portfolio
14.5.3.3. SWOT Analysis
14.5.3.4. Strategic Overview
14.5.3.5. Financial Overview
14.5.4. Bayer AG
14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.4.2. Product Portfolio
14.5.4.3. SWOT Analysis
14.5.4.4. Strategic Overview
14.5.4.5. Financial Overview
14.5.5. Bristol-Myers Squibb Company
14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.5.2. Product Portfolio
14.5.5.3. SWOT Analysis
14.5.5.4. Strategic Overview
14.5.5.5. Financial Overview
14.5.6. F. Hoffman-La Roche Ltd.
14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.6.2. Product Portfolio
14.5.6.3. SWOT Analysis
14.5.6.4. Strategic Overview
14.5.6.5. Financial Overview
14.5.7. GlaxoSmithKline plc.
14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.7.2. Product Portfolio
14.5.7.3. SWOT Analysis
14.5.7.4. Strategic Overview
14.5.7.5. Financial Overview
14.5.8. Johnson & Johnson Services, Inc.
14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.8.2. Product Portfolio
14.5.8.3. SWOT Analysis
14.5.8.4. Strategic Overview
14.5.8.5. Financial Overview
14.5.9. Merck & Co., Inc.
14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.9.2. Product Portfolio
14.5.9.3. SWOT Analysis
14.5.9.4. Strategic Overview
14.5.9.5. Financial Overview
14.5.10. Pfizer Inc.
14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.10.2. Product Portfolio
14.5.10.3. SWOT Analysis
14.5.10.4. Strategic Overview
14.5.10.5. Financial Overview
14.5.11. Sanofi
14.5.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.11.2. Product Portfolio
14.5.11.3. SWOT Analysis
14.5.11.4. Strategic Overview
14.5.11.5. Financial Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll